Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...
Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.
Novavax received clearance from the FDA to move forward with phase 3 clinical trials for its COVID-19-influenza combination (CIC ... confirming that the event was not related to the investigational ...
A fresh wave of disinformation about vaccines is flaring amid the 2024 campaign. The FDA's top vaccine official believes ...
“The Phase 1 clinical trial is designed to evaluate the safety, reactogenicity, and immunogenicity of ARCT-2304 as a potential vaccine to protect against the highly pathogenic H5N1 avian influenza ...
In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...
The aTIV vaccine provides better protection against influenza-related medical encounters than the HD-TIV vaccine in high-risk older adults.
Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...
Seasonal influenza epidemics impose substantial burdens on healthcare systems and cause >5 million hospitalizations of adults each year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback